Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706881 | 1.00 | MAOB (0.44) | MAOBTLR4TLR2SLC6A2SLC6A4 | |
| SCHEMBL30074482 | 0.89 | MAOB (0.53) | MAOBTLR4TLR2SMN1; SMN2KDM1A | |
| SCHEMBL931640 | 0.89 | MAOB (0.53) | MAOBTLR4TLR2SMN1; SMN2KDM1A | |
| SCHEMBL18707017 | 0.83 | SLC6A2 (0.41) | MAOBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16180720 | 0.83 | MAOB (0.50) | MAOBTLR4TLR2 | |
| SCHEMBL19399879 | 0.83 | MAOB (0.50) | MAOBTLR4TLR2 | |
| SCHEMBL18734265 | 0.82 | RAB9A (0.54) | MAOBTLR4TLR2SMN1; SMN2KDM1A | |
| SCHEMBL20518442 | 0.82 | RAB9A (0.54) | MAOBTLR4TLR2SMN1; SMN2KDM1A | |
| SCHEMBL18706982 | 0.82 | RAB9A (0.54) | MAOBTLR4TLR2SMN1; SMN2KDM1A | |
| SCHEMBL2209407 | 0.81 | TLR4 (0.52) | MAOBTLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | MAOB 1021/4885TLR4 3598/4885TLR2 2965/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | MAOB 1021/4885TLR4 3598/4885TLR2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.